Interim Analysis (IA) of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients (Pts) with High-Risk Large B Cell Lymphoma (LBCL)

Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research